• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硼二吡咯亚甲基染色可能增强MAFLD斑马鱼模型中的脂肪检测:经NGS验证的lncRNA分析

Boron-dipyrromethene Staining May Enhance Fat Detection in the MASLD Zebrafish Model: NGS-validated lncRNA Profiling.

作者信息

Jung Wookjae, Kim Min Hye, Yang Jung Wook, Kim Dong Chul, Lee Jong Sil, Lee Jeong-Hee, An Hyo Jung, Song Dae Hyun

机构信息

Department of Pathology, Gyeongsang National University Hospital, Jinju, Republic of Korea.

Department of Pathology, Gyeongsang National University School of Medicine, Jinju, Republic of Korea.

出版信息

In Vivo. 2025 Mar-Apr;39(2):749-757. doi: 10.21873/invivo.13879.

DOI:10.21873/invivo.13879
PMID:40010962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11884486/
Abstract

BACKGROUND/AIM: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a serious global public health concern. Long non-coding RNAs (lncRNAs) have been identified as key contributors to MASLD pathogenesis. Zebrafish can be utilized to study the relationship between MASLD and lncRNAs because of their similarity to human genes. Oil Red O staining is a traditional method for confirming liver fatty changes; however, it has several limitations. This study aimed to evaluate the efficacy of boron-dipyrromethene (BODIPY) in detecting fatty changes in the liver.

MATERIALS AND METHODS

Liver tissues were collected from 30 zebrafish that were fed a BODIPY-containing high-cholesterol diet. Oil Red O and BODIPY staining were evaluated by two pathologists, and next-generation sequencing (NGS) was performed using liver tissues categorized into high fatty change (six liver tissues) and low fatty change (six liver tissues) groups.

RESULTS

BODIPY and Oil Red O staining of zebrafish liver sections correlated significantly (=0.009). NGS identified eight differentially expressed lncRNAs with over a 10-fold difference between the high- and low-fatty acid change groups. Of these, three showed lncRNA-mRNA interaction networks linked to human disorders.

CONCLUSION

BODIPY staining is a reliable alternative to Oil Red O staining for assessing fatty changes in MASLD zebrafish models, particularly when examining frozen liver sections.

摘要

背景/目的:代谢功能障碍相关脂肪性肝病(MASLD)是一个严重的全球公共卫生问题。长链非编码RNA(lncRNAs)已被确定为MASLD发病机制的关键因素。由于斑马鱼与人类基因相似,可用于研究MASLD与lncRNAs之间的关系。油红O染色是确认肝脏脂肪变化的传统方法;然而,它有几个局限性。本研究旨在评估硼二吡咯亚甲基(BODIPY)检测肝脏脂肪变化的效果。

材料与方法

从30只喂食含BODIPY高胆固醇饮食的斑马鱼中收集肝脏组织。由两位病理学家评估油红O和BODIPY染色,并对分为高脂肪变化组(六个肝脏组织)和低脂肪变化组(六个肝脏组织)的肝脏组织进行二代测序(NGS)。

结果

斑马鱼肝脏切片的BODIPY和油红O染色显著相关(=0.009)。NGS鉴定出八个差异表达的lncRNAs,在高脂肪酸变化组和低脂肪酸变化组之间有超过10倍的差异。其中,三个显示出与人类疾病相关的lncRNA-mRNA相互作用网络。

结论

对于评估MASLD斑马鱼模型中的脂肪变化,BODIPY染色是油红O染色的可靠替代方法,特别是在检查冷冻肝脏切片时。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e757/11884486/54809761c044/in_vivo-39-753-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e757/11884486/54809761c044/in_vivo-39-753-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e757/11884486/54809761c044/in_vivo-39-753-g0001.jpg

相似文献

1
Boron-dipyrromethene Staining May Enhance Fat Detection in the MASLD Zebrafish Model: NGS-validated lncRNA Profiling.硼二吡咯亚甲基染色可能增强MAFLD斑马鱼模型中的脂肪检测:经NGS验证的lncRNA分析
In Vivo. 2025 Mar-Apr;39(2):749-757. doi: 10.21873/invivo.13879.
2
Long noncoding RNAs associated with nonalcoholic fatty liver disease in a high cholesterol diet adult zebrafish model.与高胆固醇饮食成年斑马鱼模型中非酒精性脂肪性肝病相关的长非编码 RNA。
Sci Rep. 2021 Nov 26;11(1):23005. doi: 10.1038/s41598-021-02455-0.
3
EEF1A2 identified as a hub gene associated with the severity of metabolic dysfunction-associated steatotic liver disease.EEF1A2被鉴定为与代谢功能障碍相关脂肪性肝病严重程度相关的枢纽基因。
Mamm Genome. 2025 Mar;36(1):93-105. doi: 10.1007/s00335-024-10078-9. Epub 2024 Oct 16.
4
Inhibition of mmu_circ_0009303 improves metabolic dysfunction-associated steatotic liver disease by regulating lipid metabolism and oxidative stress.抑制mmu_circ_0009303通过调节脂质代谢和氧化应激改善代谢功能障碍相关脂肪性肝病。
Endocr J. 2025 Jan 6;72(1):79-91. doi: 10.1507/endocrj.EJ24-0008. Epub 2024 Oct 24.
5
NORAD exacerbates metabolic dysfunction-associated steatotic liver disease development via the miR-511-3p/Rock2 axis and inhibits ubiquitin-mediated degradation of ROCK2.去甲肾上腺素通过miR-511-3p/Rock2轴加剧代谢功能障碍相关脂肪性肝病的发展,并抑制泛素介导的ROCK2降解。
Metabolism. 2025 Mar;164:156111. doi: 10.1016/j.metabol.2024.156111. Epub 2024 Dec 20.
6
Circular RNA RRM2 alleviates metabolic dysfunction-associated steatotic liver disease by targeting miR-142-5p to increase NRG1 expression.环状 RNA RRM2 通过靶向 miR-142-5p 增加 NRG1 表达来减轻与代谢功能障碍相关的脂肪性肝病。
Am J Physiol Gastrointest Liver Physiol. 2024 Oct 1;327(4):G485-G498. doi: 10.1152/ajpgi.00255.2023. Epub 2024 Jul 23.
7
Optimizing methods for the study of intravascular lipid metabolism in zebrafish.优化斑马鱼血管内脂质代谢研究方法。
Mol Med Rep. 2015 Mar;11(3):1871-6. doi: 10.3892/mmr.2014.2895. Epub 2014 Nov 7.
8
Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.幽门螺杆菌感染通过脂质代谢途径加重代谢功能障碍相关脂肪性肝病:一项转录组学研究。
J Transl Med. 2024 Jul 29;22(1):701. doi: 10.1186/s12967-024-05506-y.
9
Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.细胞核内的miR-204-3p可减轻小鼠代谢功能障碍相关脂肪性肝病。
J Hepatol. 2024 Jun;80(6):834-845. doi: 10.1016/j.jhep.2024.01.029. Epub 2024 Feb 6.
10
Rbm39 ameliorates metabolic dysfunction-associated steatotic liver disease by regulating Apob and Fabp4.Rbm39通过调节载脂蛋白B(Apob)和脂肪酸结合蛋白4(Fabp4)改善代谢功能障碍相关的脂肪性肝病。
Biochim Biophys Acta Mol Basis Dis. 2025 Jun;1871(5):167815. doi: 10.1016/j.bbadis.2025.167815. Epub 2025 Mar 26.

本文引用的文献

1
Structural Features and Physiological Associations of Human 14-3-3ζ Pseudogenes.人类14-3-3ζ假基因的结构特征与生理关联
Genes (Basel). 2024 Mar 24;15(4):399. doi: 10.3390/genes15040399.
2
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges.瑞美替隆,首个获批用于治疗代谢功能障碍相关脂肪性肝炎的药物:试验、机遇与挑战。
Metabolism. 2024 May;154:155835. doi: 10.1016/j.metabol.2024.155835. Epub 2024 Mar 19.
3
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
4
Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment.基于 3D 重建的荧光染色脂滴分析用于肝脂肪变性评估。
J Vis Exp. 2023 Jun 2(196). doi: 10.3791/65206.
5
An optimized method for Oil Red O staining with the salicylic acid ethanol solution.一种用水杨酸乙醇溶液优化的油红 O 染色方法。
Adipocyte. 2023 Dec;12(1):2179334. doi: 10.1080/21623945.2023.2179334.
6
Long non-coding RNAs: definitions, functions, challenges and recommendations.长非编码 RNA:定义、功能、挑战与建议。
Nat Rev Mol Cell Biol. 2023 Jun;24(6):430-447. doi: 10.1038/s41580-022-00566-8. Epub 2023 Jan 3.
7
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.代谢相关性脂肪性肝病(MAFLD)的分子机制:脂质代谢途径的功能分析。
Clin Sci (Lond). 2022 Sep 30;136(18):1347-1366. doi: 10.1042/CS20220572.
8
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.代谢相关脂肪性肝病各亚型在中年人群中的长期心血管结局存在差异。
Hepatol Int. 2022 Dec;16(6):1308-1317. doi: 10.1007/s12072-022-10407-7. Epub 2022 Sep 7.
9
Long noncoding RNAs associated with nonalcoholic fatty liver disease in a high cholesterol diet adult zebrafish model.与高胆固醇饮食成年斑马鱼模型中非酒精性脂肪性肝病相关的长非编码 RNA。
Sci Rep. 2021 Nov 26;11(1):23005. doi: 10.1038/s41598-021-02455-0.
10
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.KASL临床实践指南:非酒精性脂肪性肝病的管理
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.